Exact Sciences (EXAS) Tops Q4 EPS by 6c

Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.18), $0.06 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $87.4 million versus the consensus estimate of $85.74 million.

GUIDANCE:

Exact Sciences sees FY2018 revenue of $420-430 million, versus the consensus of $422.13 million.

• completed Cologuard test volume of 900,000-920,000 tests during 2018.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• CVG to join Russell 2000 and Russell 3000 indexes June 26
• Worthington Industries (WOR) Misses Q4 EPS by 9c